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n INTRODUCTION
Urothelial Bladder Cancer (BC) is the 11th most diagnosed malignancy, 3 out of 4 being 
non-muscle-invasive (NMIBC) [1]. The bacillus 
Calmette–Guérin (BCG) vaccine, a live attenuat-
ed strain of Mycobacterium bovis, was first intro-
duced in humans in 1921 and intravesical BCG 
immunotherapy is indicated in high- and inter-
mediate-risk NMIBCs, as it decreases the risk of 
progression and enhances disease-specific and 
overall survival [2, 3]. 
Nonetheless, BCG administration may be associ-
ated with a broad spectrum of side effects. Over-
all, their incidence ranges from 69.5% to 91%, 
including chemical cystitis, while major adverse 
reactions occur in less than 5% of the cases [4]. 
Among severe systemic manifestations, sepsis, 
granulomatous hepatitis, miliary pneumonitis, 
bone marrow involvement, soft tissue infections, 
vascular aneurysms, arthritis and uveitis are de-
scribed [5]. 
Pulmonary involvement is a rare complication oc-
curring between 0.3 and 0.7% of treated patients, 
presenting as interstitial pneumonitis or miliary 
dissemination [4, 6]. Only a few cases of miliary 
BCGitis have been reported. The suggested first-
line treatment is the combination of isoniazid, 
rifampicin, and ethambutol for 6 months, since 
M. bovis is intrinsically resistant to pyrazinamide, 
and low-level isoniazid resistance has been de-
scribed in some strains [7, 8].
Currently, no clear and standardized recom-
mendations are present regarding the diagnostic 
work-up in case of miliary pulmonary BCGitis 
suspicion. We report a case of miliary pulmonary 
BCGitis, complicated by sub-clinical pulmonary 
thromboembolism, focusing on the diagnostic 
workup and on the diagnostic delay perhaps 
due to initial empirical treatment with fluoro-
quinolones. 
Miliary pulmonary infection  
after BCG intravesical instillation:  
a rare, misdiagnosed and mistreated 
complication
Giorgio Calleris1, Giancarlo Marra1, Silvia Corcione2, Marco Oderda1, Chiara Cardellino2, 
Sabrina Audagnotto2, Bruno Frea1, Francesco Giuseppe De Rosa2, Paolo Gontero1
1University of Turin, AOU “Città della Salute e della Scienza di Torino”, Department of Surgical Sciences,  
Urology, Turin, Italy;
2University of Turin, AO “Amedeo di Savoia”, Department of Medical Sciences, Infectious Diseases, Turin, Italy
Intravesical Bacillus Calmette-Guérin (BCG) immu-
notherapy decreases the progression risk of non-mus-
cle-invasive bladder cancer, but potentially yields a 
broad spectrum of side effects. We report the case of a 
73-year-old man affected by miliary pulmonary BCG 
infection, whose microbiological diagnosis was proba-
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bly hindered by empiric fluoroquinolones, focusing on 
imaging and clinical work-up.
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n CASE REPORT 
A 73-year-old man presented to the accident and 
emergency (A&E) department of our hospital in 
March 2016, reporting intermittent fever with 
evening peak of 39°C, arisen few hours after the 
last BCG instillation, severe fatigue and sweating. 
Medical history included asthma (in treatment 
with montelukast  per os and budesonide/formo-
terol inhalation) and a diagnosis of T1G3 NMIBC 
with 9 subsequent instillations of BCG immuno-
therapy (Connaught, ImmuCyst; CytoChemia, 
Ihringen, Germany), the last of which a week be-
fore the admission. Physical examination, vitals, 
ECG and chest X-ray were normal. Laboratory 
tests revealed elevated liver enzymes (AST 105 
UI/l, ALT 129 UI/l) and a CRP of 19.1 mg/l. 
Urine and blood cultures, serological tests for 
HBV, HCV, HIV, CMV and sputum Acid-Fast 
Bacilli (AFB) testing were negative. Urinalysis 
showed the presence of sterile pyuria. Prior to 
hospital admission, the patient had been treated 
empirically with ofloxacin per os (300 mg, twice 
daily) for 3 days. Clinical findings associated with 
anamnesis prompted to systemic BCG infection 
and an anti-tubercular treatment with isoniazid 
300 mg/die, rifampin 600 mg/die and ethambu-
tol 1200 mg/die intravenously was started. After 
9 days, the patient was discharged in good gen-
eral conditions and antitubercular therapy was 
continued per os.
However, re-admission occurred a week later be-
cause of persisting fatigue, malaise, intermittent 
fever and night sweats. Specific treatment was 
continued and, again, blood tests were normal ex-
cept for a CRP of 73.5 mg/l, for liver cytolysis en-
zymes being still slightly above the normal range 
(AST 48 UI/l, ALT 65 UI/l), and for a cholestatic 
pattern (GGT 318 UI/l, ALP 324 UI/l, total biliru-
bin 1.2 mg/100ml, direct bilirubin of 0.6 mg/100 
ml). Further serological investigations were per-
formed, including EBV, Brucellosis, Salmonellosis 
and Parvovirus, all being negative.
To investigate pulmonary and urinary tract in-
volvement, a contrast-enhanced chest and abdo-
men CT-scan was performed, demonstrating a bi-
lateral pulmonary miliary pattern consistent with 
the diagnosis of miliary BCGitis (Figure 1). Fur-
thermore, pulmonary embolism of some segmen-
tal and sub-segmental arteries was diagnosed. 
No deep venous thrombosis (DVT) was observed 
at lower limbs Doppler ultrasound, suggesting 
a local origin of thromboembolism. The patient 
was treated with low molecular weight heparin 
(LMWH). 
Further evaluation revealed a PCR-based rap-
id detection test for Mycobacterium tuberculosis 
being positive in one out of two sputum speci-
mens; conversely, the same test was negative on 
the bronchoalveolar lavage (BAL). FAB test and 
cultures were negative both on sputum and BAL 
samples; QuantiFERON® test was also negative, 
as quite expected due to the absence in BCG strain 
of the peptidic antigens routinely used in ISGRAs 
assay (RD-1 region, ESAT-6 and CFP-10).
Night sweats abruptly stopped two weeks af-
ter the second admission, whereas fever and 
fatigue gradually diminished. A second con-
trast-enhanced chest CT scan at the beginning 
of April 2016 showed a reduction in pulmonary 
micro-nodule number and the complete resolu-
tion of pulmonary segmental and sub-segmental 
Figure 1 - Chest CT imaging at admission, showing miliary BCG infection.
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embolism. The patient was discharged in good 
general conditions and continued anti-tubercular 
therapy.
n DISCUSSION
Miliary pulmonary BCGitis is a very rare compli-
cation of intravesical BCG immunotherapy, but it 
needs to be promptly diagnosed and treated due 
to its non-negligible attributable mortality. Its in-
cidence is reported up to 2.3% in retrospective se-
ries, and was recently estimated 0.4% in a large, 
prospective, multi-centre study [4, 5]. 
Normal response to intravesical BCG involves an 
increase of CD4 Th1 and in gd T cells within the 
bladder mucosa, but the mechanism underlying 
the reported complication is not fully understood 
[9]. Both type 4 hypersensitivity reaction and hae-
matogenous dissemination of M. bovis in tissues 
with consequent infection may be involved [10]. 
On the one hand, different reports have shown 
the presence of viable bacilli inside the lesions 
or have detected mycobacterial genome by PCR 
assays, suggesting a significant role for a dissem-
inated BCG infection [11]. On the other hand, 
some Authors use the negative results of cultures 
and of serological and molecular tests, along with 
the successful use of steroids, to support their 
hypothesis that the granulomas in BCG disease 
are due to a hypersensitivity reaction and not to 
infection [12]. In our patient, the search for ac-
id-fast bacilli performed on sputum, blood, and 
bronco-alveolar lavage returned negative, and 
only a single PCR-based test on a sputum sample 
proved positive. 
This inability to identify M. bovis in affected tis-
sues is not entirely unexpected: the specific role of 
fluoroquinolones (FQ) administration in delaying 
diagnosis and reducing the yield of microbiology 
should be also considered in this case. Similarly, 
in a study enrolling 33 patients with tuberculosis, 
16 had received empiric levofloxacin treatment 
for CAP: the delay in the initiation of an appro-
priate treatment was 21 days in the FQ group and 
5 days in the non-FQ group [13]. In a case-control 
study from Canada, out of 148 isolates of M. tuber-
culosis, 3 were FQ resistant and patients who had 
received multiple FQ prescriptions were more 
likely than patients who had received a single 
FQ prescription to be infected with FQ-resistant 
M. tuberculosis (15.0% vs. 0.0%; odds ratio, 11.4; 
P<.04) [14]. 
Our patient presented with intermittent fever, 
malaise and night sweats, making the anamnestic 
knowledge of previous BCG treatment essential 
for diagnosis. According to the literature, inter-
mittent fever without any apparent origin, fatigue 
and malaise are frequently present at BCGitis on-
set. Patients often experience other non-specific 
symptoms including chills, dry cough, dyspnoea, 
weight loss and night sweats. Rarer findings are 
haemoptysis, arthralgia, pancytopenia and jaun-
dice, secondary to concurrent granulomatous 
hepatitis [5, 10, 11, 15]. The absence of specific 
genitourinary or pulmonary symptoms often 
helps in including miliary BCG infection in the 
differential diagnosis. 
Typically, clinical findings arise from a few days 
to a couple of weeks after the last BCG instilla-
tion, within the first months of therapy; however, 
miliary BCGitis can show up even years after the 
start of the BCG regimen [15]. Low grade fever 
arising within 24h after instillation can represent 
the normal immune response to BCG: in most 
cases, it is self-limiting and does not require an-
ti-tuberculous therapy [16]. Nevertheless, our pa-
tient experienced fever immediately after a BCG 
instillation, thus showing the need for a careful 
evaluation of this initial sign of infection. 
From our case, several crucial steps of a suspected 
BCGitis evaluation can be derived. First, as point-
ed out by a recent review, serological tests and 
blood cultures are negative in approximately 60% 
of cases, being useful especially for differential 
diagnosis purposes [5]. Instead, in early phases, 
rapid PCR-based molecular tests, either on blood, 
sputum or BAL samples, can often identify the 
agent [17]. 
Second, a chest CT scan should be performed in 
case of a negative chest X-ray and miliary BCGitis 
suspicion, as the latter misses up to 25% of miliary 
patterns [5, 11]. Therefore, early use of PCR-based 
tests together with CT-scan seems indicated to 
establish a prompt diagnosis and to start therapy 
without delay. 
Third, when an appropriate therapy is started, 
the prognosis is generally favourable, although 
a 5.4% attributable mortality was observed by 
Pérez-Jacoiste Asín et al., due to respiratory, liver 
and multi-organ failure [5]. Response to therapy 
can itself confirm the diagnosis on ex juvantibus 
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criterion. As in our case, it is important to bear in 
mind that clinical improvement often occurs after 
more than two weeks, sometimes boosted by the 
introduction of glucocorticosteroids [10, 12].
Finally, host’s characteristics, including the extent 
of bladder mucosal damage and immunosup-
pression status, are considered more important 
than therapeutic regimen features, as the number 
of intravesical instillations, the total dose admin-
istered and the number of previous TURBs; in our 
case, miliary BCGitis presented after 9 instilla-
tions. A recent large RCT could not actually prove 
any difference in side-effects rates between 1yr- 
and 3yr-mainteinance schedule, and between full 
dose and reduced dose protocols [4, 5]. 
Regarding the use of intravesical BCG in patients 
treated with low dose of oral and/or inhaled ste-
roids, retrospective studies have shown efficacy 
and safety profile of this treatment [18]. Moreover, 
also EAU guidelines does not consider inhaled 
steroids as an absolute or relative contraindica-
tion to BCG administration [8]. 
Pulmonary thromboembolism is a not uncommon 
complication in tuberculosis patients, in whom a 
hypercoagulable state could be induced by high 
plasma fibrinogen, reactive thrombocytosis, direct 
endothelial damage and use of rifampicin [19]. 
No routine prophylaxis protocol has demonstrat-
ed long-term efficacy for systemic BCG infections 
prevention [4]. Safety criteria, including delayed 
BCG administration (not during the first 2 weeks 
after resection), absence of urinary tract infection, 
non-traumatic catheterisation, immunocompe-
tent patients or absence of local or systemic symp-
toms are well established and important to reduce 
BCG administration side effects [10, 16]. A better 
urological know-how and safer administration 
techniques seem associated with a decreasing in-
cidence of adverse events. In any case, when the 
possibility of BCGitis is considered, considering 
the non-negligible mortality of this condition, a 
correct and prompt diagnostic work-up is need-
ed, and fluoroquinolones should be consistently 
avoided.
In conclusion:
 – Systemic BCGitis has to be suspected in all pa-
tients presenting with a history of BCG instil-
lations and persistent fever, associated or not 
with other non-specific or respiratory symp-
toms (malaise, weakness, chills, cough, dys-
pnoea, abnormal sweating).
 – Serological tests and blood cultures prove fre-
quently negative. Rapid PCR-based molecular 
tests, either on blood, sputum or BAL samples, 
though having higher sensitivity, can miss the 
diagnosis in approximately 50% of cases.
 – Empiric fluoroquinolones can hinder micro-
biologic diagnosis and should therefore be 
avoided when suspecting systemic BCGitis.
 – A chest CT scan should be performed in case 
of a negative chest X-ray and suspicion of sys-
temic dissemination of BCG.
 – Clinical improvement can take several weeks, 
after appropriate anti-tubercular therapy is 
started. 
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